Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Zepbound

Daily weight loss pill achieves main goal in late-stage trial

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

The Independent UK

2 Outstanding ‘Strong Buy’ Stocks to Grab in August

2 Outstanding ‘Strong Buy’ Stocks to Grab in August

These two stocks offer a rare combination of income and growth.

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Investors Business Daily

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

The Future of Weight-Loss Drugs for Investors

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Eli Lilly Stock Nears Another Record As Drugmaker Enters The Weight-Loss Arena

Eli Lilly Stock Nears Another Record As Drugmaker Enters The Weight-Loss Arena

Eli Lilly stock is Monday's IBD Stock Of The Day. Shares are forming a new flat base after the FDA approved Lilly's new weight-loss drug.

Investors Business Daily

People

Ania Jastreboff

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

305,984 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play